Agenus Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 5, 2024 Deadline to file Lead Plaintiff Motion

Core Viewpoint - A class action lawsuit has been filed against Agenus Inc. for allegedly making false or misleading statements regarding its immuno-oncology treatments, leading to significant investor losses during the specified class period [1][4]. Group 1: Company Overview - Agenus Inc. is a biotechnology company focused on developing immuno-oncology treatments, specifically two main products: balstilimab, an anti-PD-1 treatment, and botensilimab (AGEN1181), a CTLA-4 blocking antibody [3]. Group 2: Allegations of the Lawsuit - The lawsuit claims that Agenus failed to disclose that the combination of botensilimab and balstilimab was less effective than represented and that the clinical results and potential for regulatory and commercial success were overstated [4]. - On July 18, 2024, Agenus disclosed that the FDA advised against seeking Accelerated Approval for their immunotherapy combination due to insufficient evidence of improved survival rates, resulting in a nearly 59% drop in stock price [5].